|
Characteristics
|
Cutaneous adverse reactions
|
SJS/TEN
|
|---|
|
EMa (N = 122)
|
SJS/TEN (N = 132)
|
P value
|
Stevens–Johnson Syndrome (N = 73)
|
SJS–TEN overlapb (N = 18)
|
Toxic epidermal necrolysis (N = 41)
|
P value
|
|---|
|
Episodes as main diagnosis—n (%)
|
34 (27.9)
|
89 (66.4)
| |
45 (61.6)
|
14 (77.8)
|
30 (68.3)
| |
|
6-years incidence (per million inhabitants)
|
12.2
|
13.2
| |
7.3
|
1.8
|
4.1
| |
|
Gender—n (%)
|
|
Male
|
43 (35.2)
|
60 (45.5)
|
0.098
|
34 (46.6)
|
9 (50.0)
|
17 (41.5)
|
0.798
|
|
Female
|
79 (64.8)
|
72 (54.5)
| |
39 (53.4)
|
9 (50.0)
|
25 (58.5)
| |
|
Age (years)
|
|
Median (percentile 25–75)
|
63 (44–77)
|
63 (45–75)
|
0.903
|
64 (46–79)
|
57 (34–72)
|
65 (48–74)
|
0.492
|
|
Comorbidities
|
|
Hypertension
|
39 (32.0)
|
46 (34.8)
|
0.627
|
29 (39.7)
|
5 (27.8)
|
12 (29.3)
|
0.422
|
|
Diabetes
|
19 (15.6)
|
22 (16.7)
|
0.813
|
13 (17.8)
|
4 (22.2)
|
5 (12.2)
|
0.589
|
|
Heart failure
|
10 (8.2)
|
13 (9.8)
|
0.647
|
8 (11.0)
|
3 (16.7)
|
2 (4.9)
|
0.272
|
|
Chronic kidney disease
|
12 (9.8)
|
15 (11.4)
|
0.693
|
7 (9.6)
|
4 (22.2)
|
4 (9.8)
|
0.340
|
|
Liver disease
|
11 (9.0)
|
10 (7.6)
|
0.677
|
4 (5.5)
|
3 (16.7)
|
3 (7.3)
|
0.203
|
|
Acute toxic hepatitis
|
7 (5.7)
|
6 (4.5)
|
0.882
|
2 (2.7)
|
2 (11.1)
|
2 (4.9)
|
0.269
|
|
HIV
|
2 (1.6)
|
12 (9.1)
|
0.009
|
8 (11.0)
|
3 (16.7)
|
1 (2.4)
|
0.115
|
|
Length-of-stayc (days)
|
|
Median (percentile 25–75)
|
10 (5–20)
|
15 (7–28)
|
0.007
|
15 (7–23)
|
23 (9–36)
|
14 (7–28)
|
0.456
|
|
In-hospital mortality—n (%)
|
9 (7.4)
|
32 (24.2)
|
< 0.001
|
12 (16.4)
|
2 (11.1)
|
18 (43.9)
|
0.002
|
- aEncompasses 5 cases of EM minor, 11 cases of EM major, 10 cases of other forms of EM, and 96 cases of unspecified EM
- bStevens–Johnson and toxic epidermal necrolysis overlap syndrome
- cIncludes all episodes, including those resulting in the death of patients
